

## 2002 CAP TODAY Article Index

**Note: This index does not include CAP TODAY “Marketplace” or “Abstracts”**

### **AACC meetings**

It's showtime: news from the AACC pressroom, 10/02:68

### **AIDS/HIV/other bloodborne diseases**

Testing for HIV mutations hard to resist, 5/02:1 \*

Window watchers—eyeing NAT's impact, 10/02:1 \*

### **Allergy testing**

Lab-based allergy testing on the march, 4/02:1 \*

### **Analyzer surveys (see Instrumentation/instrument surveys)**

### **Anthrax (see Bioterrorism)**

### **Antibiotics**

Antibiotic alert—labs, pharmacies take on cost and misuse, 5/02:1 \*

### **ASCP/CAP meetings**

Accolades for seven at ASCP/CAP annual meeting, 11/02:86

CAP annual stated meeting minutes, 11/02:86

### **Automation**

Brainy solutions: replacing intelligence with intelligence in automated systems (lab automation systems and workcells), 5/02:88

Turning up the volume on lab automation, 6/02:44 \*

Automation takes on fine details, bigger picture, 7/02:46 \*

Believe it or not—do-it-yourself lab automation, 8/02:1 \*

Order in the blood bank: automation steps up, 10/02:1 \*

Automation site visits: making the trek to the trenches, 11/02:1 \*

### **Bethesda System**

Bethesda 2001, 3/02:10

### **Billing**

Taking a bite out of billing, coding errors, 7/02:1 \*

Bringing outreach billing back to life, 8/02:1 \*

### **Bioinformatics**

Getting ready for the bioinformatics shakeup, 8/02:64 \*

### **Bioterrorism**

Newsbytes: Logging on to combat bioterrorism, 01/02:76

Acting on anthrax—what one lab learned, 2/02:5 \*  
Letter: Testing for terror, 3/02:11  
Letter: Testing for terror, 4/02:12  
Newsbytes: New bioterrorism response information products, 6/02:110

### **Blood/coagulation/hematology**

Mutations add up to thrombophilic risk, 1/02:1 \*  
Letter: Labor savings, 1/02:8  
Q&A: Do stoppers or stopper byproducts cause crossmatch interferences? (Puca), 1/02:78 \*  
Q&A: Phlebotomy and veins above an IV: Is there a recommended waiting time before drawing from the vein after an IV is turned off? (Kiechle), 4/02:102 \*  
Steering sepsis along the coag course, 6/02:1 \*  
Perks plus: the new hematology analyzers, 6/02:1 \*  
Chasing after the causes of platelet disorders, 6/02:20 \*  
Q&A: What is the minimal percentage of specimens that should show significant hemolysis? (Kiechle), 6/02:114 \*  
Beyond blood cells: stem cells' startling potential, 7/02:66 \*  
Shortchanged: dollars don't add up for prothrombin home monitoring, 8/02:44 \*  
Q&A: Counting body fluid WBC using a hemocytometer and reporting results (Galagan), 8/02:80 \*  
Blood pressure: new Q-Probe looks at types and screens for scheduled surgeries, 9/02:60 \*  
Q&A: Is plasma from venous blood or arterial blood the preferred specimen for determining accurate ammonia levels? (Burnett), 9/02:98 \*  
Quick on the draw—coagulation tube response, 10/02:38 \*  
Q&A: Tests and parameters used to diagnose sickle cell beta thalassemia (Hoyer), 11/02:102 \*  
Blood and money: pay gap could derail blood safety, 12/02:22 \*  
A CPT overhaul for hematology, 12/02:58 \*

### **Blood banking/transfusion**

Tightening the reins on surgical blood procedures, 3/02:5 \*  
Order in the blood bank: automation steps up, 10/02:1  
Window watchers—eyeing NAT's impact, 10/02:1 \*  
Getting serious about platelet contamination, 12/02:1 \*

### **Board of Governors**

Declaration of professional responsibility: medicine's social contract with humanity, 6/02:15 \*

### **Cancer**

Breast specimens: FNA, core, more, 2/02:1 \*  
Making the call on HER2 testing methods, 2/02:1 \*  
Bladder markers gunning for green light, 3/02:1 \*  
Q&A: Does typing of mucins by histochemistry have practical applications in neoplastic surgical pathology? (Brown), 3/02:81 \*  
What went wrong? Lessons learned from breast pathology malpractice claims, 4/02:46 \*

Catching ovarian cancer with time to spare, 7/02:1 \*

Melanoma claims: from overreaction to oversight, 8/02:59 \*

Brainteaser—1p/19q deletions in gliomas, 9/02:1 \*

Lightening the cancer protocols' data demands, 9/02:1 \*

Genes pointing the way in lymphoma prognosis, 9/02:30 \*

Q&A: When to monitor methotrexate levels after administering a single dose (Schreiber), 9/02:96 \*

Steering clear of malpractice claims, 11/02:38 \*

Pap and HPV DNA testing: Is there room for both? 12/02:1 \*

More time permitted to bring cancer protocols onboard, 12/02:5 \*

### **CAP Foundation**

CAP Foundation honors contributors, 10/02:66

Donors include Foundation in their estate planning: protect your assets, set philanthropic plans, 10/02:67

Helping those who take us into the future, 10/02:67

One man's reason to give, 10/02:67

### **CAP checklists/guidelines/practice parameters/publications**

New CAP manual: beyond the blame game—putting QA through its paces in AP laboratories, 4/02:34 \*

Q&A: CAP recommendations regarding "addendum," "amended," and "corrected" in surgical pathology reports (Fitzgibbons), 5/02:104 \*

Q&A: Does CAP require checking positive urine proteins with sulfosalicylic acid? (Rabinovitch), 8/02:80 \*

Lightening the cancer protocols' data demands, 9/02:1 \*

Sketching out changes in the microbiology checklist, 11/02:20 \*

More time permitted to bring cancer protocols onboard, 12/02:5 \*

### **CAP PAP/NGC Programs Review**

Bringing in Bethesda 2001: How the University of Kentucky made the switch, 1/02:43

Using five-year retrospective reviews to manage risk, improve quality, 1/02:43

Bethesda System 2001, 1/02:44

Looking for lost slides, 1/02:44

Letter to clinicians, University of Kentucky Cytology Laboratory, 1/02:44

Q&A: How to classify biopsy of the lung that is squamous cell carcinoma, 1/02:45

Liquid-based Pap testing benefits becoming clear, 1/02:46

Before litigation, blinded rescreeing a must, 5/02:55

CAP Guidelines for Review of Pap Tests in the Context of Litigation or Potential Litigation, 5/02:55

Guidelines for cervical cytology practice, 5/02:56

More recommended reading: CAP quality improvement manual, 5/02:56

Q&A: Unsatisfactory slides and diagnosis of bronchial alveolar lavage, 5/02:56

What to tell clinicians about the Pap test, 5/02:60

Putting HPV testing into everyday practice, 8/02:35 (correction: October 2002, page 6)

Where do Pap program slides come from? 8/02:35

New requirement for nongyn TAT, 8/02:38

How to become a cytopathology inspector, 8/02:38  
Managing women with abnormal results, 8/02:39

### **CAP Surveys**

Line backers—support grows for linearity Surveys, 11/02:82 \*

### **Capitol Scan**

Protecting lab samples from radiation, 1/02:80  
Worries over CLIA waivers, 1/02:80  
Medicare enrollment made easier, 1/02:80  
Fee schedule comment process now official, 1/02:80  
Privacy revisions due first quarter '02, 1/02:80  
Labs accommodated in NC agent registry, 2/02:92  
Data standard reg delayed, 2/02:92  
CAP seeks recognition of accredited labs, 2/02:93  
New Medicare fee formula before Congress, 3/02:84  
Court orders professional component bills to be paid, 3/02:85  
Better surveillance with SNOMED, 3/02:85  
Certification for PhD laboratory directors, 3/02:85  
Bundling proposal considered a bust, 3/02:87  
Effects of payment cuts clear—CAP, 4/02:104  
A 'useless' medical record, 4/02:104  
What to do with Medicare overpayments, 4/02:104  
For genetic tests, state backs CAP standards, 4/02:105  
Staving off a reporting burden, 5/02:105  
Keeping labs out of biological agent bills, 5/02:105  
Inspections for waived labs, 5/02:105  
Pap test in New York bill, 5/02:107  
Privacy rule still problematic, 5/02:107  
Two pathologists on quality institute panel, 5/02:107  
Study: CMS can correct payment errors, 6/02:110  
New layer of certification averted, 6/02:112  
Seeking support for Part A, 6/02:110  
Senate women rally for annual Pap coverage, 7/02:124  
How to approach genetic testing focus of CAP meeting, 7/02:124  
Amend pharmacist measure, says CAP, 7/02:124  
College blood products advocacy pays off, 7/02:126  
Setback in PC billing case, 8/02:81  
A close look at lab fees, 8/02:81  
Waived is wrong for rapid HIV, 8/02:82  
How to comply with HIPAA . . . , 9/02:104  
. . . and how the final and original rules differ, 9/02:104  
Lab payment recommendations are in, 9/02:105  
Strengthen Part A language, 10/02:89  
New national test coverage policies, 10/02:89  
Delay cuts, wait for data, 10/02:90  
A call for physician pay increases, 10/02:90

Waived status not right for rapid HIV tests, 10/02:90  
Advocacy scholarships, 10/02:90  
Wait for blood cost data, 11/02:110  
Encouraging error reporting, 11/02:110  
Leave CLIA in place, 11/02:110  
A vote for liability reform, 11/02:112  
CAP accreditation written into Missouri law, 11/02:112  
No hope for a physician fee fix this year, 12/02:66  
No search for HIPAA violators, 12/02:66  
Noll, Leonard nominated to genetics panel, 12/02:66  
New 'quality systems' rule, 12/02:67  
Good news for J-1 residents, 12/02:67

### **Cardiovascular disease/cardiac markers**

Mutations add up to thrombophilic risk, 1/02:1 \*  
Q&A: Reference intervals, determinations, and protocols for troponin assays (Apple), 1/02:78 \*  
BNP, IMA assays: getting a jump on cardiovascular disease, 3/02:1 \*  
Bedside bull's-eye? POC cardiac tests gaining acceptance, 4/02:1 \*

### **Careers**

Holding out for the right job, 3/02:32 \*

### **Cholesterol testing**

Q&A: Validity of determining a lipid profile during first 24 hours after myocardial infarction (Myers), 5/02:104 \*  
One year later, cholesterol guidelines sinking in, 7/02:1 \*  
Q&A: What internal and external variables affect abnormal values for triglycerides when Zocor or Lipitor is prescribed? (Myers), 7/02:120 \*  
Q&A: What guidance is available for interpreting direct LDL measurements? (Myers, Cooper), 7/02:120 \*

### **Commentary**

PathPAC's winning ticket, and a fond farewell, 12/02:6

### **Consolidation**

Merged platforms: bargain or breaking point? 8/02:1 \*

### **Core laboratories**

Core chores—making the core lab work, 3/02:1 \*

### **Corrections/clarifications**

Correction (from "Getting the scoop on nutrition testing," January 2002, page 1), 3/02:8  
Erratum (CPT code for HPV testing from "Putting HPV testing into everyday practice," August 2002, page 35), 10/02:6

### **Cost accounting**

Money order: hunting down the true costs of POC testing, 9/02:14 \*

### **CPT questions/coding**

Use of code 88108 when preparing Thin Prep slides from FNA; use of FNA performance codes, 2/02:92

Use of code 88141 to review negative Pap tests of women at high risk for cancer, 2/02:92

Use of molecular cytogenetic codes 88271–88275 with surgical pathology code 88365 for FISH testing of HER2/neu cancers, 4/02:104

Moving bone marrow biopsy and aspiration codes within *CPT 2002*, 4/02:105

Using code 10021 for superficial FNA, 6/02:110

Selecting the proper electron microscopy code, 6/02:110

Codes and modifiers for reporting services provided outside the U.S., 8/02:81

Coding an unsatisfactory Pap test under the new Bethesda System, 8/02:81

The correct way to report immunocytochemistry stains, 10/02:90

Use of code 87207 in processing Tzanck smears, 10/02:90

In CPT '03, clinical laboratory changes only, 12/02:58 \*

A CPT overhaul for hematology, 12/02:58 \*

Reporting an apheresis code with an evaluation and management code, 12/02:66

Choosing the proper code when comparing slides and reports from different procedures conducted in different years to assess the site of origin of recurrent tumor, 12/02:66

### **Cytopathology/histology (see also CAP PAP/NGC Programs Review)**

Letter: Histology labs, 1/02:11

Q&A: "Happy cards" and negative Pap tests (Dechene), 5/02:104 \*

New Pap guidelines are here—and now the real work begins, 6/02:1 \*

Giving cytotechs a breather on manual Pap test screening, 10/02:1 \*

Pap and HPV DNA testing: Is there room for both? 12/02:1 \*

### **Diabetes**

Clamping down: How tight should glycemic control be?, 3/02:56 \*

Q&A: Policy on when to perform glucose tolerance test when patient's fasting blood sugar is high (Winter), 8/02:80 \*

### **Digital imaging**

Zooming into the future—digital pioneers forge ahead, 2/02:12 \*

Blazing another path through digital wilderness, 2/02:16 \*

### **Direct access testing**

Old debate, new state—direct access test law passes, 11/02:5 \*

### **DNA analysis**

DNA deluge, 10/02:22 \*

### **Down syndrome**

Letter: Down syndrome screening, 1/02:12

### **Editorials of CAP president (see President's Desk)**

## **Electrophoresis**

Changing lanes with capillary electrophoresis, 1/02:14 \*

## **Executive War College**

Executive War College: Stuck on survival? It's time to move on, 3/02:54

Taking a bite out of billing, coding errors, 7/02:1 \*

Taking care of business as HIPAA draws near, 9/02:5 \*

## **Firsthand Views**

In praise of boredom, 01/02:86

The art of the compliment, 2/02:102

What the worst and best have in common, 3/02:94

Smothered by 'managaholics', 4/02:110

The new formality, 5/02:114

Let the employee beware, 6/02:122

Believing in the magic boss, 7/02:146

Getting off to a good start, 8/02:90

The safety in honesty, 9/02:110

Your biggest weakness, 10/02:98

Dare to be miserable, 11/02:122

Is there a better way?, 12/02:78

## **Gastroenterology**

Q&A: Is plasma from venous blood or arterial blood the preferred specimen for determining accurate ammonia levels? (Burnett), 9/02:98 \*

## **Genetics**

Catching ovarian cancer with time to spare, 7/02:1 \*

Brainteaser—1p/19q deletions in gliomas, 9/02:1 \*

Genes pointing the way in lymphoma prognosis, 9/02:30 \*

## **Genomics**

Leaping beyond the genome—what lies ahead?, 7/02:54 \*

DNA deluge, 10/02:22 \*

## **Health care reform/legislation**

At last, more uniform coverage for high-volume tests, 1/02:5 \*

## **Hepatitis**

Q&A: When will a vaccine be available for hepatitis C? (Sandler), 2/02:91 \*

Two-way street for HCV test algorithm, 4/02:1 \*

## **HER2**

Making the call on HER2 testing methods, 2/02:1 \*

Q&A: Procedures for performing, reporting, and billing for HER2 (Hammond), 10/02:86 \*

## **HIPAA**

Newsbytes: HIPAA compliance guide, 1/02:76  
Newsbytes: Bush extends deadline for HIPAA rule, 2/02:88  
Taking care of business as HIPAA draws near, 9/02:5 \*  
Capitol Scan: How to comply with HIPAA . . . , 9/02:104  
Capitol Scan: . . . and how the final and original rules differ, 9/02:104  
HIPAA and CAP-accredited labs, 12/02:20

## **Industry trends**

Merged platforms: bargain or breaking point? 8/02:1 \*  
Getting ready for the bioinformatics shakeup, 8/02:64 \*

## **Infectious disease surveillance**

Cleaning up the clutter in disease reporting, 5/02:5 \*

## **Information systems, technologies (see also Bioinformatics and Automation)**

Seeing the light on LIS data conversion, 1/02:1 \*  
Expert systems a feast for leaner laboratories, 1/02:54 \*  
Value of add-ons to eradicate errors adds up (anatomic pathology computer systems), 2/02:20  
Special delivery: Laboratories are distributing their goods by way of the Web—and finding it works, 4/02:16 \*  
Tying up loose ends with a lab project database, 5/02:20 \*  
Physician office-lab links software: latest and greatest or a flash of the past?, 5/02:24  
Brainy solutions: replacing intelligence with intelligence in automated systems (lab automation systems and workcells), 5/02:88  
Turning up the volume on lab automation, 6/02:44 \*  
Adding up billing system offerings (billing/accounts receivable systems), 7/02:33  
Automation takes on fine details, bigger picture, 7/02:46 \*  
Blood bank information systems: need for software savvy in push for patient safety, 10/02:56 \*  
Helping clinicians cope with CPOE systems, 11/02:1 \*  
Putting the question "Which is best?" to the test (laboratory information systems), 11/02:54 \*

## **Innovations in Pathology**

Improving laboratory use, 6/02:116  
Oh what a tangled web we weave, 6/02:117  
Improving laboratory use, 9/02:99  
Digital photography, 9/02:100  
PDAs in pathology, 9/02:102  
Prostatic cancer screening, 12/02:69  
Handling prostatic cores, 12/02:69  
Marking methods, 12/02:69

## **Instrumentation/instrument surveys**

Changing lanes with capillary electrophoresis, 1/02:14 \*

Coagulation analyzers, 1/02:29  
New tools for netting POC connectivity, 2/02:1 \*  
Glucose analyzers 2002—sweeter than ever (bedside glucose testing systems), 3/02:64  
A solution for any service challenge (automated immunoassay analyzers), 4/02:58  
Perks plus: the new hematology analyzers, 6/02:1 \*  
Don't leave patient safety to the roll of the dice (chemistry analyzers for low-volume labs), 6/02:60  
Chemistry analyzers branching out (chemistry analyzers for mid- and high-volume labs), 7/02:84  
Coagulation analyzers (point-of-care, self-monitoring), 8/02:52  
Blood gas analyzer basics—and beyond (in vitro blood gas analyzers), 9/02:62 \*  
New and improved: hematology analyzers (high-volume hematology analyzers), 12/02:36 \*

### **Internet/intranets**

Special delivery: Laboratories are distributing their goods by way of the Web—and finding it works, 4/02:16 \*

### **Laboratory Accreditation News/CLA programs**

Winds of change—training, checklists, pricing, 2/02:83  
Comparing PT results can put a lab's CLIA license on the line, 2/02:84  
Brushing up on the latest provisos, ideas, 6/02:99 \*  
Three R's and more at core of commission meeting, 10/02:76 \*

### **Laboratory Accreditation News: Queries and Comments**

Compliance and TAT for nongyn cytology cases, 2/02:83  
Conducting comparability testing between two different sites as it applies to GEN.30050, 2/02:83  
Assessing interferences according to AGC.24130 in the checklist, 6/02:99  
Making the checklist booklet easier to use, 6/02:100  
Intent of GEN.40530's inclusion in laboratory general checklist, 10/02:76  
Competency and training of nonlaboratory personnel for phlebotomy techniques, 10/02:76  
Performing and documenting Allen's test/collateral circulation test and AGC.22400, 10/02:77

### **Legal issues**

What went wrong? Lessons learned from breast pathology malpractice claims, 4/02:46 \*  
What went wrong? Learn to confirm—lessons from a core needle case, 5/02:72 \*  
Melanoma claims: from overreaction to oversight, 8/02:59 \*  
Steering clear of malpractice claims, 11/02:38 \*  
Florida squeeze: Florida court ruling threatens professional component billing, 12/02:50 \*

### **Letters**

Labor savings, 1/02:8  
Histology labs, 1/02:11  
Down syndrome screening, 1/02:12

Nutrition testing, 3/02:8  
Bethesda 2001, 3/02:10  
Testing for terror, 3/02:10  
PAC contributions, 4/02:11  
Testing for terror, 4/02:12  
Cancer protocols, 5/02:8  
Bladder markers, 5/02:12  
Breast aspirates, 6/02:16  
PAC contributions, 6/02:16  
Bladder markers, 7/02:8  
Allergy testing, 7/02:11  
Hematology, 8/02:8  
HIV drug resistance testing, 8/02:8  
Breast core biopsy, 8/02:12  
Blinded rescreening, 8/02:12  
Hematology analyzers, 9/02:11  
CAP inspections, 9/02:12  
Billing, coding errors, 10/02:8  
Happy cards, 10/02:11  
HIPAA regulations, 11/02:11

#### **Management issues/laboratory utilization**

New tools for netting POC connectivity, 2/02:1 \*  
Core chores—making the core lab work, 3/02:1 \*  
Merged platforms: bargain or breaking point? 8/02:1 \*

#### **Medical mistakes (see Legal issues)**

#### **Medicare (see also Medicare entries under Capitol Scan)**

At last, more uniform coverage for high-volume tests, 1/02:5 \*  
Pinning reimbursement hopes on CMS powwow, 7/02:5 \*  
Fee cuts proposed; CAP to pose alternatives, 8/02:5 \*  
Shortchanged: Dollars don't add up for prothrombin home monitoring, 8/02:44 \*  
Open house: CMS welcomes lab input in fee talks, 10/02:5 \*  
Blood and money: pay gap could derail blood safety, 12/02:22 \*

#### **Microbiology**

Mutations add up to thrombophilic risk, 1/02:1 \*  
Antibiotic alert—labs, pharmacies take on cost and misuse, 5/02:1 \*  
Urinalysis finally catches up, 9/02:1 \*  
Sketching out changes in the microbiology checklist, 11/02:20 \*  
In microbiology lab, five not-so-easy pieces, 12/02:1 \*

#### **Molecular genetics (see Microbiology)**

#### **Myocardial infarction (see Cardiovascular disease/cardiac markers)**

## **NCCLS guidelines**

Line backers—support grows for linearity Surveys, 11/02:82 \*

## **Newsbytes**

Logging on to combat bioterrorism, 01/02:76  
Patient e-mail forms good practice for physicians, 01/02:76  
HIPAA compliance guide, 01/02:76  
Medscape announces agreement with Atlas, 01/02:76  
Calling up training relief, 02/02:88  
Impath to acquire Tamtron Corp., 02/02:88  
The potential of one ASP . . . , 02/02:88  
. . . the pitfalls of another, 02/02:88  
Bush extends deadline for HIPAA rule, 02/02:88  
HIMSS: a glimpse at people and products, 3/02:82  
LabSoft partners with Wyndgate, 3/02:82  
GE Medical Systems signs agreement to acquire MedicaLogic, 3/02:82  
Bio-Reference Laboratories and MedUnite band together, 3/02:84  
Schuyler House offering Internet module, 3/02:84  
New FDA guidelines for software validation may miff manufacturers, 4/02:100  
ProxyMed and ARUP enter marketing arrangement, 4/02:100  
LabSoft adds reminder feature to laboratory systems, 4/02:101  
Gem Premier blood gas analyzer on Rals-Plus system menu, 4/02:101  
Data Innovations releases Instrument Manager v. 7.04, 4/02:101  
Upgrading security of utmost importance, survey says, 5/02:101  
McKesson offers medical management platform, 5/02:101  
New power conditioner, 5/02:101  
HHS secretary pushes for paperless medical system, 5/02:103  
SNOMED releases Spanish edition of terminology, 5/02:103  
Key Communications expands printer line, 5/02:103  
Vendors working with providers on hospitals of the future, 6/02:109  
Netsteps merges with Park City Solutions, 6/02:109  
Eclipsys forms institute to manage and analyze patient data, 6/02:109  
New bioterrorism response information products, 6/02:110  
Meditech to include Digi-Trax label printing in software, 6/02:111  
Internet connectivity at root of Cerner, Hilgraeve alliance, 6/02:111  
LIS marketplace out of breadth but still going strong, 7/02:128  
Impac acquires Intellidata, 7/02:128  
Per-Se and Oracle form alliance, 7/02:128  
Bayer Diagnostics signs agreement to acquire Visible Genetics, 8/02:82  
Snips and clips of CLMA meeting, 8/02:82  
HealthcareOne offers wireless Palm OS medical dictation system, 8/02:82  
LabSoft launches reporting module for lab administration, 8/02:83  
Database for mobile health care applications, 8/02:83  
Micromedex supporting memory expansion cards, 8/02:83  
New software for Beckman Coulter data manager system, 8/02:83  
Esoterix launches EDI system, 9/02:102  
New software to control Windows operating systems, 9/02:102

SNOMED CT second release available, 9/02:103  
Upcoming AMIA meeting, 9/02:103  
Impac increases focus on international markets, 9/02:103  
Vector NTI for Mac OS X, 9/02:103  
Is voice recognition ready and able? 10/02:87  
Misys releases open clinical decision support system, 10/02:88  
Mitsubishi offering digital monochrome printer, 10/02:88  
Seacoast marketing lab link product, 10/02:88  
Aperio marketing software for viewing digital images, 10/02:88  
Dawning Technologies introduces Java-based interface engine, 10/02:88  
KLAS survey scorecard: evaluating the LIS marketplace, 11/02:108  
Need to share data driving use of electronic health record, 11/02:108  
HealthTrio partners with FlexTech, 11/02:109  
Information technology the talk of AABB meeting, 12/02:68  
Computer use growing among doctors—but not in all areas, 12/02:68  
Impac offering system to manage network traffic, 12/02:68  
Genotyping software for Luminex 100, 12/02:68  
Updated release of BioRS integration and retrieval system, 12/02:69

### **Nutrition**

Getting the scoop on nutrition testing, 1/02:1 \*  
Letter: Nutrition testing, 3/02:8

### **Obituary**

Thomas L. Gavan, MD, 1/02:12  
Jerald R. Schenken, MD, 2/02:8  
James D. Barger, MD, 6/02:16

### **Pap tests (see Cytopathology/histology)**

### **Parathyroidectomy (PTH) testing**

Picking a path for PTH testing, 5/02:1

### **PathPAC**

PathPAC's winning ticket, and a fond farewell, 12/02:6

### **Payment issues**

At last, more uniform coverage for high-volume tests, 1/02:5 \*  
Pinning reimbursement hopes on CMS powwow, 7/02:5 \*  
Bringing outreach billing back to life, 8/02:1 \*  
Fee cuts proposed; CAP to pose alternatives, 8/02:5 \*  
Shortchanged: Dollars don't add up for prothrombin home monitoring, 8/02:44 \*  
Open house: CMS welcomes lab input in fee talks, 10/02:5 \*  
Blood and money: pay gap could derail blood safety, 12/02:22 \*  
Florida squeeze: Florida court ruling threatens professional component billing, 12/02:50 \*

### **Point-of-care testing**

New tools for netting POC connectivity, 2/02:1 \*

Tightening the reins on surgical blood procedures, 3/02:5 \*

Bedside bull's-eye? POC cardiac tests gaining acceptance, 4/02:1 \*

How top-notch POC programs earn high marks, 6/02:5 \*

Money order: hunting down the true costs of POC testing, 9/02:14 \*

### **President's Desk**

Travel in time and space, 1/02:11 \*

Of tissues, organs, and pathologists, 2/02:11 \*

A new 'Focus' on what we do, 3/02:11 \*

Pathology without barriers, 4/02:11 \*

Advocacy and professionalism, 5/02:11 \*

The Panacea for our malaise, 6/02:15 \*

Cultivating the garden, 7/02:11 \*

Crisis in liability insurance coverage, 8/02:11 \*

Medical liability reform heats up, 9/02:11 \*

The move to disclose medical error, 10/02:11 \*

Turning ideas into action plans, 11/02:11 \*

The conduit of credibility, 12/02:11 \*

### **Proficiency testing (see also Laboratory Accreditation News/CLA programs)**

Comparing PT results can put a lab's CLIA license on the line, 2/02:84

### **Proteomics**

Clinical proteomics—someday, somehow, 11/02:1 \*

### **PSA testing**

Q&A: Should we be heading toward an International Normalized Ratio in PSA testing? (Bock, Klee), 11/02:106 \*

### **Q&A**

Do stoppers or stopper byproducts cause crossmatch interferences? (Puca), 1/02:78 \*

Reference intervals, determinations, and protocols for troponin assays (Apple), 1/02:78 \*

When will a vaccine be available for hepatitis C? (Sandler), 2/02:91 \*

Validity of lipid profile results done on ICU patients (Naito), 2/02:91 \*

Use of bilirubin tablet vs. bilirubin dipstick test in urinalysis (Novak), 3/02:81 \*

Does typing of mucins by histochemistry have practical applications in neoplastic surgical pathology? (Brown), 3/02:81 \*

Does CAP have guidelines for preserving unstained bone marrow slides? (Merrick), 4/02:102 \*

Is there a recommended waiting time before drawing from the vein after an IV is turned off? (Kiechle), 4/02:102 \*

"Happy cards" and negative Pap tests (Dechene), 5/02:104 \*

Validity of determining a lipid profile during first 24 hours after myocardial infarction (Myers), 5/02:104 \*

CAP recommendations regarding "addendum," "amended," and "corrected" in surgical pathology reports (Fitzgibbons), 5/02:104 \*

Does a specified manufacturer's urinalysis microscope meet CAP standards? (Gruber), 6/02:113 \*

What is the minimal percentage of specimens that should show significant hemolysis? (Kiechle), 6/02:114 \*

How to report albumin/creatinine ratio on a random urine specimen (Kroll), 6/02:115 \*

What internal and external variables affect abnormal values for triglycerides when Zocor or Lipitor is prescribed? (Myers), 7/02:120 \*

What guidance is available for interpreting direct LDL measurements? (Myers, Cooper), 7/02:120 \*

Does CAP require checking positive urine proteins with sulfosalicylic acid? (Rabinovitch), 8/02:80 \*

Counting body fluid WBC using a hemocytometer and reporting results (Galagan), 8/02:80 \*

Policy on when to perform glucose tolerance tests when a patient's fasting blood sugar is high (Winter), 8/02:80 \*

Is plasma from venous blood or arterial blood the preferred specimen for determining accurate ammonia levels? (Burnett), 9/02:98 \*

When to monitor methotrexate levels after administering a single dose (Schreiber), 9/02:96 \*

Does the CAP have guidelines for releasing gallstones to patients? (Merrick, Carter), 10/02:86 \*

Procedures for performing, reporting, and billing for HER2 (Hammond), 10/02:86 \*

Tests and parameters used to diagnose sickle cell beta thalassemia (Hoyer), 11/02:102 \*

How many cassettes should a histotechnologist process during an eight-hour shift? (Brown, et al), 11/02:102 \*

Should we be heading toward an International Normalized Ratio in PSA testing? (Bock, Klee), 11/02:106 \*

Lipemic specimens and the coag section: Are additives available to break up the lipemia as there are in chemistry? (Adcock, Ramanathan; Makar), 12/02:64 \*

### **Q-Tracks/Q-Probes**

It's all in the numbers with Q-Tracks and Q-Probes, 8/02:18 \*

Blood pressure: New Q-Probe looks at types and screens for scheduled surgeries, 9/02:60 \*

### **Release of specimens**

Q&A: Does the CAP have guidelines for releasing gallstones to patients? (Merrick, Carter), 10/02:86 \*

### **Screening tests**

Mutations add up to thrombophilic risk, 1/02:1 \*

Getting the scoop on nutrition testing, 1/02:1 \*

Q&A: Reference intervals, determinations, and protocols for troponin assays (Apple), 1/02:78 \*

Breast specimens: FNA, core, more, 2/02:1 \*

Making the call on HER2 testing methods, 2/02:1 \*

BNP, IMA assays: getting a jump on cardiovascular disease, 3/02:1 \*

Clamping down: How tight should glycemic control be? 3/02:56 \*

Q&A: Use of bilirubin tablet vs. bilirubin dipstick test in urinalysis (Novak), 3/02:81 \*  
Testing for HIV mutations hard to resist, 5/02:1 \*  
Picking a path for PTH testing, 5/02:1 \*  
Window watchers—eyeing NAT's impact, 10/02:1 \*  
Giving cytotechs a breather on manual Pap test screening, 10/02:1 \*  
Q&A: Tests and parameters used to diagnose sickle cell beta thalassemia (Hoyer),  
11/02:102 \*

### **Self-testing (see Point-of-care testing)**

#### **Sepsis**

Steering sepsis along the coag course, 6/02:1 \*

#### **SNOMED**

Merging terminologies for a new mother tongue, 4/02:5 \*  
Newsbytes: SNOMED releases Spanish edition of terminology, 5/02:103  
Newsbytes: SNOMED CT second release available, 9/02:103

#### **Staffing**

Letter: Histology labs, 1/02:11  
Holding out for the right job, 3/02:32 \*  
Q&A: How many cassettes should a histotechnologist process during an eight-hour shift?  
(Brown, et al), 11/02:102 \*

#### **Stem cells**

Beyond blood cells: stem cells' startling potential, 7/02:66 \*

#### **Tumor markers**

Bladder markers gunning for green light, 3/02:1 \*

#### **Urinalysis**

Q&A: Use of bilirubin tablet vs. bilirubin dipstick test in urinalysis (Novak), 3/02:81 \*  
Q&A: Does a specified manufacturer's urinalysis microscope meet CAP standards?  
(Gruber), 6/02:113 \*  
Q&A: How to report albumin/creatinine ratio on a random urine specimen (Kroll),  
6/02:115 \*  
Urinalysis finally catches up, 9/02:1 \*